View Future GrowthGrifols 과거 순이익 실적과거 기준 점검 3/6Grifols의 수입은 연평균 -4.1%의 비율로 감소해 온 반면, Biotechs 산업은 수입이 연평균 13.3% 증가했습니다. 매출은 연평균 9.3%의 비율로 증가해 왔습니다. Grifols의 자기자본이익률은 6.3%이고 순이익률은 5.6%입니다.핵심 정보-4.07%순이익 성장률-8.35%주당순이익(EPS) 성장률Biotechs 산업 성장률14.79%매출 성장률9.28%자기자본이익률6.31%순이익률5.58%최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트Reported Earnings • May 11First quarter 2026 earnings releasedFirst quarter 2026 results: EPS: €0.11. Revenue: €1.70b (down 4.8% from 1Q 2025). Net income: €73.0m (up 22% from 1Q 2025). Profit margin: 4.3% (up from 3.3% in 1Q 2025). Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.공시 • Feb 25Grifols, S.A. to Report Fiscal Year 2025 Results on Feb 26, 2026Grifols, S.A. announced that they will report fiscal year 2025 results at 5:35 PM, Central European Standard Time on Feb 26, 2026Reported Earnings • Jul 30Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: €1.89b (up 4.0% from 2Q 2024). Net income: €117.1m (up €102.2m from 2Q 2024). Profit margin: 6.2% (up from 0.8% in 2Q 2024). Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Europe.공시 • May 12Grifols, S.A. to Report Q1, 2025 Results on May 12, 2025Grifols, S.A. announced that they will report Q1, 2025 results on May 12, 2025모든 업데이트 보기Recent updates공시 • May 18Grifols, S.A., Annual General Meeting, Jun 17, 2026Grifols, S.A., Annual General Meeting, Jun 17, 2026. Location: parque empresarial can sant joan, avinguda de la generalitat, sant cugat del valles, barcelona., SpainReported Earnings • May 11First quarter 2026 earnings releasedFirst quarter 2026 results: EPS: €0.11. Revenue: €1.70b (down 4.8% from 1Q 2025). Net income: €73.0m (up 22% from 1Q 2025). Profit margin: 4.3% (up from 3.3% in 1Q 2025). Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.공시 • Feb 25Grifols, S.A. to Report Fiscal Year 2025 Results on Feb 26, 2026Grifols, S.A. announced that they will report fiscal year 2025 results at 5:35 PM, Central European Standard Time on Feb 26, 2026Valuation Update With 7 Day Price Move • Feb 03Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €9.98, the stock trades at a forward P/E ratio of 14x. Average trailing P/E is 17x in the Biotechs industry in Europe. Total loss to shareholders of 25% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €18.75 per share.공시 • Jan 09Grifols, S.A. Announces Board Changes, Effective January 1, 2026Grifols, S.A. Board of Directors resolved to unanimously approve, with effect from January 1, 2026, the appointment of Ms. Laura de la Cruz Galán as the new Secretary non-member of the Board of Directors, replacing Mrs. Núria Martín Barnés, and the appointment of Mrs. Núria Martín Barnés as the new Vice-secretary non-member of the Board of Directors, replacing Ms. Laura de la Cruz Galán.Valuation Update With 7 Day Price Move • Dec 18Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €11.85, the stock trades at a forward P/E ratio of 14x. Average trailing P/E is 17x in the Biotechs industry in Europe. Total returns to shareholders of 12% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €21.17 per share.New Risk • Dec 14New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 2.8x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.8x net interest cover). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (6.7% average weekly change).New Risk • Nov 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (5.9% average weekly change).Valuation Update With 7 Day Price Move • Nov 24Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to €9.33, the stock trades at a forward P/E ratio of 13x. Average trailing P/E is 18x in the Biotechs industry in Europe. Total loss to shareholders of 7.8% over the past three years.Upcoming Dividend • Aug 04Upcoming dividend of €0.12 per shareEligible shareholders must have bought the stock before 11 August 2025. Payment date: 13 August 2025. The company last paid an ordinary dividend in October 2014. The average dividend yield among industry peers is 2.1%.New Risk • Jul 31New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 3.0x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (3.0x net interest cover). Minor Risks Share price has been volatile over the past 3 months (5.5% average weekly change). Large one-off items impacting financial results.Reported Earnings • Jul 30Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: €1.89b (up 4.0% from 2Q 2024). Net income: €117.1m (up €102.2m from 2Q 2024). Profit margin: 6.2% (up from 0.8% in 2Q 2024). Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Europe.Board Change • Jun 25High number of new directorsIndependent Director Pascal Ravery was the last director to join the board, commencing their role in 2024.공시 • May 12Grifols, S.A. to Report Q1, 2025 Results on May 12, 2025Grifols, S.A. announced that they will report Q1, 2025 results on May 12, 2025공시 • May 03Grifols, S.A., Annual General Meeting, Jun 04, 2025Grifols, S.A., Annual General Meeting, Jun 04, 2025. Location: parque empresarial can sant joan, avinguda de la generalitat, 152-158, 08174 sant cugat del valles, barcelona SpainValuation Update With 7 Day Price Move • Apr 04Investor sentiment deteriorates as stock falls 21%After last week's 21% share price decline to €8.18, the stock trades at a forward P/E ratio of 12x. Average trailing P/E is 21x in the Biotechs industry in Europe. Total loss to shareholders of 50% over the past three years.매출 및 비용 세부 내역Grifols가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이BIT:1GRF 매출, 비용 및 순이익 (EUR Millions)날짜매출순이익일반관리비연구개발비31 Mar 267,4384151,09837431 Dec 257,5244021,14538030 Sep 257,5183731,13938630 Jun 257,4462971,12237431 Mar 257,3721951,16436931 Dec 247,2121571,16536330 Sep 247,0061611,39138630 Jun 246,8111491,27737931 Mar 246,6561891,38438531 Dec 236,592421,37339530 Sep 236,535231,34338830 Jun 236,479-51,21738831 Mar 236,358471,34539001 Jan 236,0641851,19636130 Sep 225,5491491,13835330 Jun 225,207661,12235831 Mar 225,0161121,06435931 Dec 214,9331891,06235530 Sep 215,0443611,04633730 Jun 215,1996671,00831131 Mar 215,23156299229831 Dec 205,34061998629430 Sep 205,39268797128830 Jun 205,35355797628631 Mar 205,23569795928131 Dec 195,09962594327630 Sep 194,96155292327130 Jun 194,79056587826131 Mar 194,62056885924931 Dec 184,48759781524130 Sep 184,33269977721230 Jun 184,24670480421531 Mar 184,27967280021931 Dec 174,31866386022530 Sep 174,34857185723030 Jun 174,29155982722231 Mar 174,15355481020931 Dec 164,05054577519830 Sep 164,01453777121630 Jun 163,98653577621831 Mar 163,98552976822131 Dec 153,93553273622430 Sep 153,78953369621130 Jun 153,645507686199양질의 수익: 1GRF는 €156.2M 규모의 큰 일회성 손실이 있어 31st March, 2026까지 지난 12개월 재무 결과에 영향을 미쳤습니다.이익 마진 증가: 1GRF의 현재 순 이익률 (5.6%)은 지난해 (2.6%)보다 높습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 1GRF의 수익은 지난 5년 동안 연평균 4.1% 감소했습니다.성장 가속화: 지난 1년간 1GRF 의 수익 증가율(112.6%)은 연간 평균(-4.1%)을 초과합니다.수익 대 산업: 1GRF의 지난 1년 수익 증가율(112.6%)은 Biotechs 업계의 39.9%를 상회했습니다.자기자본이익률높은 ROE: 1GRF의 자본 수익률(6.3%)은 낮음으로 평가됩니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/25 12:39종가2026/05/25 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Grifols, S.A.는 32명의 분석가가 다루고 있습니다. 이 중 11명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관null nullBanco de Sabadell. S.A.Luis ArredondoBanco de Sabadell. S.A.Jaime EscribanoBanco Santander29명의 분석가 더 보기
Reported Earnings • May 11First quarter 2026 earnings releasedFirst quarter 2026 results: EPS: €0.11. Revenue: €1.70b (down 4.8% from 1Q 2025). Net income: €73.0m (up 22% from 1Q 2025). Profit margin: 4.3% (up from 3.3% in 1Q 2025). Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.
공시 • Feb 25Grifols, S.A. to Report Fiscal Year 2025 Results on Feb 26, 2026Grifols, S.A. announced that they will report fiscal year 2025 results at 5:35 PM, Central European Standard Time on Feb 26, 2026
Reported Earnings • Jul 30Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: €1.89b (up 4.0% from 2Q 2024). Net income: €117.1m (up €102.2m from 2Q 2024). Profit margin: 6.2% (up from 0.8% in 2Q 2024). Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Europe.
공시 • May 12Grifols, S.A. to Report Q1, 2025 Results on May 12, 2025Grifols, S.A. announced that they will report Q1, 2025 results on May 12, 2025
공시 • May 18Grifols, S.A., Annual General Meeting, Jun 17, 2026Grifols, S.A., Annual General Meeting, Jun 17, 2026. Location: parque empresarial can sant joan, avinguda de la generalitat, sant cugat del valles, barcelona., Spain
Reported Earnings • May 11First quarter 2026 earnings releasedFirst quarter 2026 results: EPS: €0.11. Revenue: €1.70b (down 4.8% from 1Q 2025). Net income: €73.0m (up 22% from 1Q 2025). Profit margin: 4.3% (up from 3.3% in 1Q 2025). Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.
공시 • Feb 25Grifols, S.A. to Report Fiscal Year 2025 Results on Feb 26, 2026Grifols, S.A. announced that they will report fiscal year 2025 results at 5:35 PM, Central European Standard Time on Feb 26, 2026
Valuation Update With 7 Day Price Move • Feb 03Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €9.98, the stock trades at a forward P/E ratio of 14x. Average trailing P/E is 17x in the Biotechs industry in Europe. Total loss to shareholders of 25% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €18.75 per share.
공시 • Jan 09Grifols, S.A. Announces Board Changes, Effective January 1, 2026Grifols, S.A. Board of Directors resolved to unanimously approve, with effect from January 1, 2026, the appointment of Ms. Laura de la Cruz Galán as the new Secretary non-member of the Board of Directors, replacing Mrs. Núria Martín Barnés, and the appointment of Mrs. Núria Martín Barnés as the new Vice-secretary non-member of the Board of Directors, replacing Ms. Laura de la Cruz Galán.
Valuation Update With 7 Day Price Move • Dec 18Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €11.85, the stock trades at a forward P/E ratio of 14x. Average trailing P/E is 17x in the Biotechs industry in Europe. Total returns to shareholders of 12% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €21.17 per share.
New Risk • Dec 14New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 2.8x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.8x net interest cover). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (6.7% average weekly change).
New Risk • Nov 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (5.9% average weekly change).
Valuation Update With 7 Day Price Move • Nov 24Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to €9.33, the stock trades at a forward P/E ratio of 13x. Average trailing P/E is 18x in the Biotechs industry in Europe. Total loss to shareholders of 7.8% over the past three years.
Upcoming Dividend • Aug 04Upcoming dividend of €0.12 per shareEligible shareholders must have bought the stock before 11 August 2025. Payment date: 13 August 2025. The company last paid an ordinary dividend in October 2014. The average dividend yield among industry peers is 2.1%.
New Risk • Jul 31New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 3.0x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (3.0x net interest cover). Minor Risks Share price has been volatile over the past 3 months (5.5% average weekly change). Large one-off items impacting financial results.
Reported Earnings • Jul 30Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: €1.89b (up 4.0% from 2Q 2024). Net income: €117.1m (up €102.2m from 2Q 2024). Profit margin: 6.2% (up from 0.8% in 2Q 2024). Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Europe.
Board Change • Jun 25High number of new directorsIndependent Director Pascal Ravery was the last director to join the board, commencing their role in 2024.
공시 • May 12Grifols, S.A. to Report Q1, 2025 Results on May 12, 2025Grifols, S.A. announced that they will report Q1, 2025 results on May 12, 2025
공시 • May 03Grifols, S.A., Annual General Meeting, Jun 04, 2025Grifols, S.A., Annual General Meeting, Jun 04, 2025. Location: parque empresarial can sant joan, avinguda de la generalitat, 152-158, 08174 sant cugat del valles, barcelona Spain
Valuation Update With 7 Day Price Move • Apr 04Investor sentiment deteriorates as stock falls 21%After last week's 21% share price decline to €8.18, the stock trades at a forward P/E ratio of 12x. Average trailing P/E is 21x in the Biotechs industry in Europe. Total loss to shareholders of 50% over the past three years.